S7
Based on 1 publication(s) in Google Scholar
S7 is an inhibitory polypeptide targeting IL-6R, which specifically binds to IL-6R and its A chain (gp80/IL-6RA) to block its signal transduction. S7 inhibits IL-6-mediated anti-apoptosis (apoptosis), angiogenesis and the expression of VEGF-A, blocks related survival signaling pathways, and enhances the sensitivity of cancer cells to chemotherapeutic drugs. S7 can be applied to the research of related diseases such as cervical cancer, multiple myeloma, Kaposi's sarcoma, prostate cancer and basal cell carcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.53%
- CAS 番号: 853248-13-2
- 分子式: C37H70N10O10
- 分子量:815.01
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
MedChemExpress(MCE)の使用を引用している文献 S7
MoreVEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
IL-6Ra |
VEGFR1 |
体外実験
S7 (1012 pfu/mL; 1 h) potently inhibits the binding of IL-6 to purified IL-6Rα in a cell-free competitive binding ELISA assay[1].
S7 (5×106 pfu/mL; 2 h) specifically binds to membrane-bound IL-6Rα on C33A, HeLa, Siha, BCC and HEK293 cell lines, but does not bind to IL-6Rα-negative HUVEC cells[1].
S7 inhibits the binding of IL-6 to membrane-bound IL-6Rα on C33A, HeLa, Siha, BCC and HEK293 cell lines[1].
S7 (50 μM; 24 h) blocks IL-6-mediated activation of the PI3-K/Akt and Ras/MAPK signaling pathways, and inhibits IL-6-induced upregulation of the anti-apoptotic protein Mcl-1 in C33A cervical cancer cells[1].
S7 inhibits IL-6-induced VEGF-A secretion in C33A cervical cancer cells, BCC cells, and RPMI 8226 multiple myeloma cells[1].
S7 inhibits the secretion of VEGF-A by C33A, BCC and RPMI 8226 cells, and blocks IL-6-induced HUVEC proliferation[1].
S7 almost completely inhibits IL-6-induced capillary-like tube formation in human umbilical vein endothelial cells (HUVECs) in vitro[1].
S7 (25-250 μM; 1 h) dose-dependently blocks the interaction between IL-6 and recombinant soluble human IL-6Rα, with significant inhibitory activity observed at concentrations of 25 μM and above[2].
S7 (50 μM; 2 h) significantly blocks the binding of IL-6 to IL-6Rα on C33A, HeLa, Siha, BCC and HEK293 cells[2].
S7 (50 μM; 24 h) sensitizes C33A cervical cancer cells to cisplatin-induced apoptosis by blocking the IL-6-mediated anti-apoptotic signaling pathway[2].
S7 (50 μM; 16 h) inhibits IL-6-induced VEGF-A protein and VEGF-A mRNA expression in C33A, RPMI 8226 and BCC cancer cells, and reduces constitutive VEGF-A expression in IL-6-overexpressing C33A/IL-6 cells[2].
S7 (50 μM; 24 h) reduces IL-6-induced VEGF-A secretion in C33A, BCC and RPMI 8226 cancer cells[2].
S7 (50 μM) inhibits IL-6-induced HUVEC proliferation by reducing pro-angiogenic factors in the conditioned media of C33A, BCC and RPMI 8226 cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:C33A, HeLa, Siha, BCC, HEK293, HUVEC
-
Concentration:5×1012 pfu/mL
-
Incubation Time:2 h
-
Result:Showed high binding affinity to all membrane-type IL-6Rα-expressing cell lines (C33A, HeLa, Siha, BCC, HEK293) but did not bind to IL-6Rα-negative HUVEC cells, with significantly higher absorbance values than the control phage S1 in IL-6Rα-positive lines.
-
Cell Line:C33A cervical cancer cell line
-
Concentration:50 μmol/L
-
Incubation Time:24 h
-
Result:Significantly inhibited IL-6-induced phosphorylation of Akt and ERK1/2, blocking activation of the PI3-K/Akt and Ras/MAPK signaling pathways.
Suppressed IL-6-induced up-regulation of the antiapoptotic Mcl-1 protein.
-
Cell Line:C33A, HeLa, Siha, BCC, HEK293
-
Concentration:50 μM
-
Incubation Time:2 h
-
Result:Significantly reduced the binding of IL-6 to IL-6Rα in all five tested cell lines compared to the S1 control peptide.
-
Cell Line:C33A cervical carcinoma cells
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Interfered with IL-6's protective effect against cisplatin-induced apoptosis.
Significantly increased the percentage of apoptotic cells compared to IL-6 plus cisplatin treatment without S7.
-
Cell Line:C33A, BCC, RPMI 8226
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Notably decreased IL-6-mediated VEGF-A secretion in all three tested cell lines compared to IL-6-treated cells without S7.
体内実験
S7 (50 mg/kg; i.p.; once every 2 days; for a total of 39 days) inhibits IL-6-induced cervical tumor growth by 76% in SCID mice through suppressing the IL-6-mediated signaling pathway, VEGF-A expression, and inducing tumor cell apoptosis[2].
S7 abrogates IL-6-induced angiogenesis in C57BL/6J mice, which is verified by the decreased hemoglobin content in Matrigel plugs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice (6- to 8-week-old female; inoculated s.c. with 1 × 106 IL-6-overexpressing C33A cervical carcinoma cells)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; every 2 days; 39 days
-
Result:Reduced IL-6-induced tumor growth by 76%.
Significantly inhibited IL-6-mediated VEGF-A expression and phosphorylation of Akt and ERK in tumor tissue.
Increased the number of apoptotic tumor cells as measured by TUNEL assay.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 853248-13-2
-
性状 Solid
-
分子量 815.01
-
分子式 C37H70N10O10
-
Color White to off-white
-
配列
Leu-Ser-Leu-Ile-Thr-Arg-Leu
-
シーケンスの短縮
LSLITRL
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Neuroinflammation
Sleep deprivation induces anxiety-like behaviors through IL-6 driven astrocyte-GABAergic neuron crosstalk in the PAG-ACC circuit. [Abstract]2026 May 22. PMID: 42174628
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (61.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
純度とドキュメンテーション
-
データシート (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2270 mL | 6.1349 mL | 12.2698 mL | 30.6745 mL |
| 5 mM | 0.2454 mL | 1.2270 mL | 2.4540 mL | 6.1349 mL | |
| 10 mM | 0.1227 mL | 0.6135 mL | 1.2270 mL | 3.0674 mL | |
| 15 mM | 0.0818 mL | 0.4090 mL | 0.8180 mL | 2.0450 mL | |
| 20 mM | 0.0613 mL | 0.3067 mL | 0.6135 mL | 1.5337 mL | |
| 25 mM | 0.0491 mL | 0.2454 mL | 0.4908 mL | 1.2270 mL | |
| 30 mM | 0.0409 mL | 0.2045 mL | 0.4090 mL | 1.0225 mL | |
| 40 mM | 0.0307 mL | 0.1534 mL | 0.3067 mL | 0.7669 mL | |
| 50 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6135 mL | |
| 60 mM | 0.0204 mL | 0.1022 mL | 0.2045 mL | 0.5112 mL |